Temporary Change in PDL Status for Antihypertensives, Sympatholytics Drug Class

Date: September 26, 2022 Attention: All Providers Effective Date: September 26, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: The Health and Human Services Commission (HHSC) is aware of a drug shortage for Catapres-TTS patches in the Antihypertensives, Sympatholytics drug class due to the discontinuation of this product by the manufacturer, Boehringer Ingelheim. HHSC received reports of a shortage from MCOs, and the manufacturer verified the shortage. How this impacts providers: Effective September 26, 2022, HHSC temporarily removed the non-preferred status from the generic product, clonidine transdermal patches, on the preferred drug list (PDL). The preferred status of the brand name products (NDC 00597-0031-34, 00597-0032-34, and 00597-0033-34) will not change to allow for any existing stock available to be utilized. HHSC removed the non-preferred status for the following generic drugs.

NDC	Generic Drug Name
00378-0871-99	CLONIDINE 0.1 MG/DAY PATCH
00591-3508-04	CLONIDINE 0.1 MG/DAY PATCH
51862-0453-04	CLONIDINE 0.1 MG/DAY PATCH
00378-0872-99	CLONIDINE 0.2 MG/DAY PATCH
00591-3509-04	CLONIDINE 0.2 MG/DAY PATCH
51862-0454-04	CLONIDINE 0.2 MG/DAY PATCH
00378-0873-99	CLONIDINE 0.3 MG/DAY PATCH
00591-3510-04	CLONIDINE 0.3 MG/DAY PATCH
51862-0455-04	CLONIDINE 0.3 MG/DAY PATCH

Next steps for providers: Prescribers should share this communication with their staff. If you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org.For access to all provider alerts,log into: www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.